This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greenberg, P. D. Articles by Fefer, A. Search for Related Content PubMed PubMed Citation Articles by Greenberg, P. D. Articles by Fefer, A.

Detection of Early and Delayed Antitumor Effects following Curative Adoptive Chemoimmunotherapy of Established Leukemia¹

Division of Oncology, Department of Medicine, University of Washington School of Medicine, and Fred Hutchinson Cancer Research Center, Seattle, Washington 98195

Advanced disseminated leukemia can be successfully eradicated by treatment with a combination of noncurative nonlethal chemotherapy plus adoptively transferred immune cells. The time course of tumor elimination following such therapy was examined by bioassay for tumor of peripheral blood and spleen cells from treated mice. Curative treatment with adoptive chemoimmunotherapy did not immediately eliminate all leukemia. Bioassay of cells from treated mice, rather, demonstrated that, following the initial tumor lysis mediated by the chemotherapy and immune cells, a period of tumor regrowth lasting several weeks preceded ultimate tumor eradication. This transient tumor regrowth detectable by bioassay never became clinically evident in the treated mice. However, immunosuppression of mice two weeks after treatment with adoptive chemoimmunotherapy resulted in recurrence of lethal tumor. The results suggest that tumor elimination following curative adoptive chemoimmunotherapy is biphasic and that the efficacy of therapy may be subject to positive and/or negative influences over a prolonged time period.

¹ This work was supported by Grant CA 10777 from the National Cancer Institute, NIH.

² Recipient of an American Cancer Society Junior Faculty Fellowship. To whom requests for reprints should be addressed.

³ Recipient of an American Cancer Society Professorship of Clinical Oncology.

Received 3/31/80. Accepted 9/ 9/80.

This article has been cited by other articles:

				P. Mirmonsef, G. Tan, G. Zhou, T. Morino, K. Noonan, I. Borrello, and H. I. Levitsky Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation Blood, February 15, 2008; 111(4): 2112 - 2121. [Abstract] [Full Text] [PDF]

				C. Ohlen, M. Kalos, D. J. Hong, A. C. Shur, and P. D. Greenberg Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen J. Immunol., February 15, 2001; 166(4): 2863 - 2870. [Abstract] [Full Text] [PDF]